Login / Signup

Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.

Ning WangZhenxian MoLu PanMinhua ZhouXiaolan YeXinjian LiuXiong CaiChanggeng QianFeili ChenYan XiongFushun FanWenyu Li
Published in: Targeted oncology (2023)
Our study provides robust evidence for the dual PI3K/HDAC inhibitor BEBT-908 as an effective anti-cancer agent for PCNSL.
Keyphrases
  • histone deacetylase
  • diffuse large b cell lymphoma
  • open label
  • clinical trial
  • cerebrospinal fluid
  • double blind